Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
PEA wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
14 of 16 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
6 of 6 studies with measurable effects showed benefit.
Top outcomes
250-500mg yeast beta-glucan OR 3g oat beta-glucan for cholesterol
Morning, With or without food
Yeast-derived 1,3/1,6 beta-glucan (Wellmune is most studied)
600-1200mg
With meals, Split into 2-3 doses
Micronized or ultra-micronized PEA
4-12 weeks
During illness
4-8 weeks
2-8 weeks
4-8 weeks
Ongoing
Galactomannans are the most effective soluble dietary fibers in type 2 diabetes: a systematic review and network meta-analysis
The American journal of clinical nutrition (2023) · Meta analysis · n=2685
Galactomannans had the highest effect on reducing the levels of HbA1c (SUCRA: 92.33%) and fasting blood glucose (SUCRA: 85.92%).
Effects of Oat Beta-Glucan Intake on Lipid Profiles in Hypercholesterolemic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Nutrients (2022) · Meta analysis · n=927
The results were presented with the weighted mean difference (WMD) with a 95% CI.
A systematic review and meta-analysis of beta-glucan consumption on glycemic control in hypercholesterolemic individuals
International journal of food sciences and nutrition (2015) · Meta analysis · n=603
Summary estimates of weighted mean differences (WMD) and 95% confidence interval was 0.05 mmol/L (-0.11, 0.02) for fasting glucose concentration and 0.75 pmol/L (-1.82, 3.32) for fasting insulin concentrations.
Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis
Nutrients (2024) · Meta analysis · n=742
These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month.
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials
Nutrients (2023) · Meta analysis · n=774
PEA was found to reduce pain scores relative to comparators in a pooled estimate, with a standard mean difference of 1.68 (95% CI 1.05 to 2.31, p = 0.00001).
Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities
Journal of psychopharmacology (Oxford, England) (2025) · Meta analysis · n=2503
Importantly, these treatments were generally well-tolerated, with no significant increase in all-cause dropouts compared to placebo, highlighting their suitability for clinical use in managing agitation in individuals with ASD or ID.
Based on multiple meta-analyses showing 0.24-0.32 mmol/L LDL reduction. Effect specific to oat beta-glucan, not yeast forms. FDA-approved health claim at 3g dose. GI side effects more common with oat forms.
Based on multiple meta-analyses showing ~35% pain reduction. Studies primarily used micronized formulations which may have better bioavailability than standard forms. Most benefits observed within 4-6 weeks of treatment.
AI-estimated from published studies. Interpret as directional guidance.
PEA has a higher evidence score (7.5/10 vs 7/10) and wins in 2 of 3 categories.
For reduce inflammation, PEA has a higher relevance score (85 vs 70).
No known interactions between Beta-Glucans and PEA have been documented in our database. However, always consult a healthcare provider before combining supplements.